Skip to content
Open access

Comparison of 3 guideline lipid emulsion regimens for local anesthetic systemic toxicity: an in silico study of bolus duration, total dose, and treatment delay in intravenous bupivacaine overdose.

Oct 2026 · Ewha Medical Journal · 0 citations · 31 references
Medicine

TL;DR

In this bupivacaine model, bolus duration distinguished the regimens more than dose did, and delay had a greater effect than either, eliminating most of the benefit without changing the lipid load.

Abstract

Purpose Lipid emulsion is the only specific antidote for local anesthetic systemic toxicity, but no dose-finding study has been conducted. We compared 3 published regimens and alternative schedules that deliver the same dose in different ways using a human model of intravenous bupivacaine overdose. Methods A 14-compartment human bupivacaine model was independently reimplemented without fitted parameters, replacing first-order lipid elimination with a saturable term. Toxicity was modeled as 112.5 mg administered intravenously over 3 minutes. Benefit was defined as the predicted maximum decrease in myocardial bupivacaine within 30 minutes, and harm as the predicted relative lipid load, indexed by peak plasma triglyceride concentration. Neither measure is a validated surrogate. Results The 3 guidelines specify the same doses but different bolus durations: 1 minute versus 2-3 minutes. At a matched dose of 12 mL/kg, myocardial bupivacaine decreased by 30.5% with the 1-minute bolus and 24.9% with the 2.5-minute bolus, with the same lipid load. The completed American Society of Regional Anesthesia and Pain Medicine regimen (7.64 mL/kg) achieved a 24.6% decrease versus 24.9% with 12 mL/kg; thus, complete regimens differ in schedule as well as dose. Repeating the 1-minute bolus twice, for a total of 4.5 mL/kg, achieved a 31.9% decrease with 62% less emulsion. Start time had the greatest effect: the best regimen achieved a 41.8% decrease when started at the end of the injection, but only 9.6% when started at 10 minutes. Conclusion In this bupivacaine model, bolus duration distinguished the regimens more than dose did, and delay had a greater effect than either, eliminating most of the benefit without changing the lipid load. Treatment should begin at the first signs of toxicity, and 20% lipid emulsion should be immediately available wherever local anesthetics are used.

Read PDF

Similar papers

Oct 2026

Evaluation of novel water soluble compositions of propofol for intravenous anesthesia.

Solubilizing propofol without lipid-associated risks-hyperlipidemia, microbial growth, and severe injection pain-remains a major formulation challenge spanning over four decades. Traditional lipid emulsions persist largely due to the difficulty of achieving high-capacity aqueous solubilization without compromising safe...

N. Wu, Fang R. Teng · 0 citations
Review Open access Oct 2026

Low-dose versus standard dose of soybean-based intravenous lipid emulsions in neonates: A systematic review and meta-analysis.

There is no difference between the use of low doses and standard doses of SO-ILE in neonates receiving parenteral nutrition with respect to liver-related, growth, or mortality outcomes.

Nágila Alves Lima, Jennifer Brito Warner, L. R. Campos et al. · 0 citations
Open access Sep 2026

Systemic Bioavailability of Topical Diclofenac: Sodium 1% Versus Diethylamine 1.16% and the Effect of Heat or Exercise in a Randomized Cross-Over Study.

Diclofenac is a widely used topical nonsteroidal anti-inflammatory drug (NSAID) for pain and inflammation. This study evaluated the relative bioavailability of diclofenac from diclofenac sodium (DS) gel 1% versus diclofenac diethylamine (DEA) gel 1.16% and assessed whether adjunct heat or moderate exercise influences s...

Karin Nicholson, M. Armogida, M. Gold et al. · 0 citations
Open access Sep 2026

The Impact of Systemic Redistribution on Cutaneous Pharmacokinetic-Based Bioequivalence: An In vivo Dermal Open Flow Microperfusion Study for Lidocaine and Prilocaine.

BACKGROUND Cutaneous pharmacokinetics (PK) can be assessed using dermal open flow microperfusion (dOFM) and dermal microdialysis (dMD). However, the dermal vasculature can clear and redistribute compounds to the skin, which may affect an assessment of bioequivalence (BE). OBJECTIVE This study verified the BE of a top...

K. Tiffner, T. Ramezanli, Beate Boulgaropoulos et al. · 0 citations
Open access Oct 2026

Bioequivalence of budesonide inhalation suspension with and without activated charcoal in healthy Chinese subjects: two randomized four-period crossover trials

The charcoal-related findings are consistent with, but do not establish, a predominant pulmonary contribution to systemic exposure after nebulization and should be interpreted cautiously because the conditions were evaluated in separate cohorts.

Yin-Juan Li, L. Qi, Rong-Xia Fan et al. · 0 citations
Open access Oct 2026

Intravenous Fat Emulsion Administration and Short-Term Lipid Profiles Under a Standardized Clinical Pathway After Gastrectomy: A Retrospective Observational Study

Background/Objectives: Real-world data on intravenous fat emulsion administration and postoperative lipid profiles under standardized clinical pathways are limited. We described administration practices and short-term lipid profiles after gastrectomy. Methods: This single-center retrospective study included patients wh...

Kazuo Kobayashi, S. Ida, Masanari Tsuji et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.